Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    IDX-1197

Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03317743
Recruitment Status : Active, not recruiting
First Posted : October 23, 2017
Last Update Posted : January 15, 2021
Sponsor:
Collaborators:
IlDong Pharmaceutical Co Ltd
National OncoVenture
Information provided by (Responsible Party):
Idience Co., Ltd.

Brief Summary:
the purpose of this open-label, dose escalation-dose expansion, Phase 1 clinical trial is to evaluate the safety, pharmacokinetics and anti-tumor activity and determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of NOV140101 (IDX-1197).

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: NOV140101 (IDX-1197) Phase 1

Detailed Description:
This is an open-label, Phase 1 dose escalation study of NOV140101 (IDX-1197) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and the anti-tumor efficacy of IDX-1197 in patients with advanced solid tumors after failure of standard of care. DLTs will be assessed as the primary endpoint in this trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label, Phase I Clinical Trial to Identify Optimal Dose and Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Anti-cancer Efficacy of NOV140101(IDX-1197HCl) in Patients With Advanced Solid Tumors
Actual Study Start Date : August 29, 2017
Actual Primary Completion Date : December 8, 2020
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: NOV140101 (IDX-1197) Drug: NOV140101 (IDX-1197)
The dose levels will be escalated following a 3+3 dose escalation scheme.
Other Name: IDX-1197




Primary Outcome Measures :
  1. Dose Limiting Toxicities (DLTs) [ Time Frame: Subjects will be treated and observed for DLT through the end of the first cycle (Days 0-21) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ≥19 year old patients with histologically or cytologically confirmed metastatic or unresectable advanced solid tumors
  • Life expectancy ≥12 weeks
  • Women of childbearing potential must have a negative pregnancy test outcome
  • ECOG performance status ≤2
  • Lesions measured by tumor markers or CT/MRI and evaluable according to RECIST v1.1
  • Patient must have adequate organ function as indicated by the following laboratory values independent of transfusion within 2 weeks:

    1. ANC ≥ 1,500/mm³
    2. Platelet count ≥ 100,000/mm³
    3. Hemoglobin ≥ 9.0g/dL
    4. Serum creatinine ≤ 1.5×ULN
    5. Total bilirubin ≤ 1.5×ULN
    6. AST, ALT ≤ 3×ULN (≤ 5×ULN for patients with liver metastasis or liver cell cancer)
    7. PT and aPTT ≤ 1.5×ULN
    8. UPC < 1.0 g/g (one re-test is allowed if positive (≥ 1))
  • Patients must provide written informed consent to voluntary participation in this study.

Exclusion Criteria:

  • History of hypersensitivity reactions to any of the components of the investigational product or other drugs of the same class
  • New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled hypertension (systolic/diastolic blood pressure >140/90mmHg), or other clinically significant cardiovascular abnormalities in the opinion of the investigator
  • Uncontrolled cardiac arrhythmia
  • Acute coronary syndrome (unstable angina pectoris or myocardial infarction) within the past 6 months
  • Major electrocardiogram (ECG) abnormalities in the opinion of the investigator
  • Severe infection or severe traumatism
  • Pneumonia or respiratory symptoms, such as dyspnea, cough, and fever, requiring treatment and other conditions likely to be accompanied by hypoxemia
  • History of drug or alcohol abuse within the past 3 months
  • Symptomatic or uncontrolled central nervous system (CNS) metastasis
  • Less than 4 weeks have elapsed since a major surgery and 2 weeks have elapsed since a minor surgery
  • Radiotherapy, hormone therapy, or chemotherapy within 2 weeks prior to baseline from which toxicities not recovered to ≤grade 1
  • >4 weeks of persistent Grade 3 (NCI-CTCAE v4.03) hematologic toxicities from prior anticancer treatment
  • History of myelodysplastic syndrome (MDS) or pre-treatment cytogenetic test results indicative of the risk of MDS or acute myelocytic leukemia
  • Ongoing or anticipated treatment with antiplatelet drugs (aspirin, clopidogrel, etc.) or anticoagulant drugs (warfarin, heparin, etc.) during the study
  • Requiring continuous treatment with systemic NSAIDs or systemic corticosteroids
  • Ongoing or past treatment with immunosuppressants within 14 days prior to the first dose of study treatment, except for intranasal, inhaled, topical, or locally injected (e.g., intraarticular injection) steroids
  • History of serious gastrointestinal bleedings within 12 weeks prior to screening or presence of diseases that may affect oral drug absorption (e.g., malabsorption syndrome, active peptic ulcer)
  • History of human immunodeficiency virus infection or active hepatitis B or C infection or ongoing uncontrolled chronic infectious disease
  • Pregnant or lactating women or patients planning to become pregnant during the study
  • Participation in another clinical trial within 30 days prior to screening
  • Individual considered ineligible for this study for other reasons, in the opinion of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03317743


Locations
Layout table for location information
Korea, Republic of
Asan Medical Center
Seoul, Songpa-gu, Korea, Republic of, 05505
Sponsors and Collaborators
Idience Co., Ltd.
IlDong Pharmaceutical Co Ltd
National OncoVenture
Layout table for additonal information
Responsible Party: Idience Co., Ltd.
ClinicalTrials.gov Identifier: NCT03317743    
Other Study ID Numbers: NOV140101-101/ID-VDP-101
First Posted: October 23, 2017    Key Record Dates
Last Update Posted: January 15, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms